brentuximab vedotin
takeda,seagen
['echelon-1']
dr. ansell, of , stopped by to share some great insights from the echelon-1 study at #asco22! don t forget to check it out 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.